We can’t show the full text here under this license. Use the link below to read it at the source.
Association of GLP-1 Receptor Agonist Use With Risk of Lumbar Degenerative Disease and Spine Surgery in Patients With Type 2 Diabetes: A Propensity Score–matched Cohort Study
Use of GLP-1 Receptor Drugs and the Risk of Lower Back Degeneration and Spine Surgery in People with Type 2 Diabetes
AI simplified
Abstract
A total of 196,435 matched pairs were analyzed, showing that GLP-1 RA users had a lower incidence of at 3 and 5 years.
- At 3 years, the incidence of lumbar degenerative disease (LDD) was 11.9% in GLP-1 RA users compared to 13.3% in non-users.
- The odds ratio for LDD at 3 years was 0.89, indicating a potential reduction in risk for GLP-1 RA users.
- At 5 years, LDD incidence further decreased in GLP-1 RA users to 14.6% versus 18.7% in non-users, with an odds ratio of 0.74.
- Rates of lumbar spine surgery were similar between groups at 3 years (0.4%), but were lower in GLP-1 RA users at 5 years (0.5% vs 0.6%).
- The odds ratio for lumbar spine surgery at 5 years was 0.86, suggesting a potential reduction in surgery risk for those using GLP-1 RAs.
AI simplified
Key numbers
11.9%
Incidence Reduction at 3 Years
GLP-1 RA users vs. non-users at 3 years
14.6%
Incidence Reduction at 5 Years
GLP-1 RA users vs. non-users at 5 years
0.5%
Lumbar Surgery Rate at 5 Years
GLP-1 RA users vs. non-users at 5 years